( CNN ) -- A second Massachusetts compounding pharmacy surrendered its license after state inspectors found `` significant '' issues that could affect sterility , state health officials said . The pharmacy , Infusion Resource , was also found to have a center for giving intravenous medications to patients in violation of state regulations , which require a clinic license , Dr. Madeleine Biondolillo , director of the Massachusetts Department of Public Health Bureau of Healthcare Safety and Quality , said Sunday . The state Board of Pharmacy immediately issued a cease and desist notice to Infusion Resource after the October 23 inspection revealed the violations , she said . Over the weekend , the Department of Public Health `` secured the voluntary surrender of Infusion 's pharmacy license . '' The company , which compounds antibiotic and nutritional IV medications for home use , said in a statement it has since recalled all compounded products dispensed in the past month , effecting 38 patients . `` No issues were cited related to the integrity of our products nor to the quality of our compounding practices , '' said Bernard Lambrese , Infusion Resource CEO , in a statement . `` It is correct that Infusion Resource does not have a clinic license from the Commonwealth of Massachusetts . The space in our facility is intended for patient education , validation of patient and caregiver skills , medication counseling , medication education , teaching and training . '' What is a compounding pharmacy ? Massachusetts Gov . Deval Patrick said last week the state would immediately begin unannounced inspections of all Massachusetts pharmacies and require that they submit annual reports detailing what they produce and distribute . That announcement came in the wake of the fungal meningitis outbreak that has caused 25 deaths and 354 illnesses , linked to the Massachusetts-based New England Compounding Center . Seven of those illnesses are peripheral joint infections that specifically affect a joint such as a knee , hip , shoulder or elbow . Infusion Resource is not linked to the outbreak . The incident began unfolding September 24 , when the department was notified about a cluster of six rare fungal meningitis cases in Tennessee . The patients shared several risk factors , including having received an epidural injection of a steroid -- methylprednisolone acetate -- that had been compounded at the NECC in Framingham . The department soon learned that the suspect product had been distributed to more than 14,000 patients in 23 states . FDA : Drug maker had internal warnings months before meningitis outbreak . The Department of Public Health has asked two other companies -- Ameridose and Alaunus Pharmaceutical -- to cease all pharmacy operations based on their shared ownership and leadership with NECC . `` NECC 's transparency in dealing with the board since inception in 1998 demonstrates its good faith intention to operate in compliance with the requirements of its license , '' said Paul Cirel , a Boston-based lawyer representing the compounder , in a statement last week . `` Furthermore , the company 's intention and best efforts at compliance are equally applicable in every other state in which it has been licensed . ''
Investigators found `` significant '' issues in an inspection of Infusion Resource . The company surrendered its pharmacy license over the weekend . A spokesman for the state Department of Health and Human Services said it was aware that a pharmacy had been shut down but declined to comment further. The inspections are conducted in the wake of a multistate meningitis outbreak .